(32) To overcome resistance and antigen escape in R/R DLBCL, research is focusing on durable strategies, including alternative antigen targeting (CD20, CD22, CD70), combination therapies, and next-generation CAR-T or bispecific antibodies (CD19/20, CD19/22, CD19/70) to expand treatment options for CD19-negative relapses. The gene discussed is CD22; the disease is diffuse large B-cell lymphoma.